Anti-cMet antibody and its use for the detection and the diagnosis of cancer
US8673302B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2010 |
| Grant date | Mar 18, 2014 |
| Priority date | — |
| Expiry date | Aug 23, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.